BB Healthcare Trust PLC Issue of Equity (9194Q)

TIDMBBH

RNS Number : 9194Q

BB Healthcare Trust PLC

02 March 2021

 
 
 
    2 March 2021 
 
    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, 
     TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH 
     AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE 
     OF DOUBT, THIS DOES NOT INCLUDE THE UK) OR TO ANY NATIONAL, 
     RESIDENT OR CITIZEN OF AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH 
     AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE 
     OF DOUBT, THIS DOES NOT INCLUDE THE UK) 
 
                           BB Healthcare Trust plc 
 
                           Issue of Ordinary Shares 
 
    BB Healthcare Trust plc (the "Company") announces that it has 
     today issued 1,425,000 of its ordinary shares of one penny each 
     ("Ordinary Shares") pursuant to its block listing facility. 
     The Ordinary Shares will be issued at a price of 189.00 pence 
     per Ordinary Share, a premium to the prevailing net asset value 
     ("cum income") per Ordinary Share. 
 
    Following the issue of Ordinary Shares, the Company's issued 
     share capital will comprise (509,280,455) Ordinary Shares and 
     this is the total number of Ordinary Shares with voting rights 
     in the Company. This figure (509,280,455) may be used by shareholders 
     as the denominator for the calculations by which they will determine 
     if they are required to notify their interest in, or a change 
     to, their interest in the Company under the Financial Conduct 
     Authority's Disclosure Guidance and Transparency Rules. 
 
    The Company's LEI is: 213800HQ3J3H9YF2UI82 
 
    For further information please contact: 
 
    Bellevue Asset Management (UK) Ltd. 
    Mark Ghahramani 
    Telephone: [phone] 
 
    J.P. Morgan Cazenove 
    James Bouverat (Sales) 
    Telephone: [phone] 
 
    Alvarium Securities Limited 
    Mark Thompson [phone] 
    Eddie Nissen [phone] 
    Oliver Kenyon [phone] 
 
 
 
    Disclaimer 
 
    This announcement does not constitute a prospectus relating 
     to the Company and does not constitute, or form part of, any 
     offer or invitation to sell or issue, or any solicitation of 
     any offer to purchase or subscribe for, any shares in the Company 
     in any jurisdiction nor shall it, or any part of it, or the 
     fact of its distribution, form the basis of, or be relied on 
     in connection with or act as any inducement to enter into, any 
     contract therefore. 
 
    J.P. Morgan Cazenove and Alvarium Securities Limited, which 
     are authorised and regulated by the Financial Conduct Authority, 
     are acting for the Company only in connection with the matters 
     described in this announcement and are not acting for or advising 
     any other person, or treating any other person as their client, 
     in relation thereto and will not be responsible for providing 
     the regulatory protection afforded to clients of Alvarium Securities 
     Limited and J.P. Morgan Cazenove or advice to any other person 
     in relation to the matters contained herein. 
 
    The shares of the Company have not been and will not be registered 
     under the US Securities Act of 1933, and may not be offered 
     or sold in the United States absent registration or an applicable 
     exemption from the registration requirements. Moreover, the 
     shares of the Company have not been, nor will they be, registered 
     under the applicable securities laws of Australia, Canada, the 
     Republic of South Africa, Japan or any member state of the EEA 
     (other than the United Kingdom). Further, the Company will not 
     be registered under the US Investment Company Act of 1940, as 
     amended. Subject to certain exceptions, the shares of the Company 
     may not be offered or sold in the United States, Australia, 
     Canada, the Republic of South Africa, Japan or any member state 
     of the EEA (other than the United Kingdom or to professional 
     investors in Ireland) or to, or for the account or benefit of, 
     any national, resident or citizen of the United States, Australia, 
     Canada, the Republic of South Africa, Japan or any member state 
     of the EEA (other than the United Kingdom or to professional 
     investors in Ireland). The share issuance programme, and the 
     distribution of this announcement, in other jurisdictions may 
     be restricted by law and the persons into whose possession this 
     announcement comes should inform themselves about, and observe, 
     any such restrictions. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFLFFRVAIFIIL

(END) Dow Jones Newswires

March 02, 2021 11:29 ET (16:29 GMT)